Literature DB >> 21881130

IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis.

Shalini Gautam1, Rajiv Kumar, Radheshyam Maurya, Susanne Nylén, Nasim Ansari, Madhukar Rai, Shyam Sundar, David Sacks.   

Abstract

The mechanisms underlying the failure to contain the growth of Leishmania parasites in human visceral leishmaniasis (VL) are not understood. L donovani amastigotes were quantified in cultured splenic aspirate cells to assess the function of IL-10 in lesional tissue ex vivo. In 67 patients with active VL, IL-10 neutralization promoted parasite killing in 73% and complete clearance in 30%, while 18% had more parasites and 9% did not change. The splenic cells secreted increased levels of both tumor necrosis factor α (TNFα) and interferon γ (IFNγ) under IL-10-neutralizing conditions. These findings provide direct support for targeting IL-10 as an approach to therapy in human VL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881130      PMCID: PMC3164427          DOI: 10.1093/infdis/jir461

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

Review 2.  IL-10: the master regulator of immunity to infection.

Authors:  Kevin N Couper; Daniel G Blount; Eleanor M Riley
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

3.  IL-10-producing T cells suppress immune responses in anergic tuberculosis patients.

Authors:  V A Boussiotis; E Y Tsai; E J Yunis; S Thim; J C Delgado; C C Dascher; A Berezovskaya; D Rousset; J M Reynes; A E Goldfeld
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 4.  Biology of interleukin-10.

Authors:  Robert Sabat; Gerald Grütz; Katarzyna Warszawska; Stefan Kirsch; Ellen Witte; Kerstin Wolk; Jens Geginat
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-05       Impact factor: 7.638

Review 5.  Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.

Authors:  Piero L Olliaro; Philippe J Guerin; Sibylle Gerstl; Astrid Aga Haaskjold; John-Arne Rottingen; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

6.  Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis.

Authors:  E M Carvalho; O Bacellar; C Brownell; T Regis; R L Coffman; S G Reed
Journal:  J Immunol       Date:  1994-06-15       Impact factor: 5.422

7.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections.

Authors:  H W Ghalib; M R Piuvezam; Y A Skeiky; M Siddig; F A Hashim; A M el-Hassan; D M Russo; S G Reed
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 9.  Interleukin-10 and the pathogenesis of human visceral leishmaniasis.

Authors:  Susanne Nylén; David Sacks
Journal:  Trends Immunol       Date:  2007-08-06       Impact factor: 16.687

10.  Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis.

Authors:  Susanne Nylén; Radheshyam Maurya; Liv Eidsmo; Krishna Das Manandhar; Shyam Sundar; David Sacks
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

View more
  84 in total

1.  Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood.

Authors:  Om Prakash Singh; Kamlesh Gidwani; Rajiv Kumar; Susanne Nylén; Stephen L Jones; Marleen Boelaert; David Sacks; Shyam Sundar
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

2.  CD8 T cell exhaustion in human visceral leishmaniasis.

Authors:  Shalini Gautam; Rajiv Kumar; Neetu Singh; Abhishek Kumar Singh; Madhukar Rai; David Sacks; Shyam Sundar; Susanne Nylén
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

3.  HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis.

Authors:  Bhawana Singh; Michaela Fakiola; Medhavi Sudarshan; Joyce Oommen; Siddharth Sankar Singh; Shyam Sundar; Jenefer M Blackwell
Journal:  Immunology       Date:  2018-11-22       Impact factor: 7.397

4.  Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

Authors:  Mona E E Elfaki; Eltahir A G Khalil; Anne S De Groot; Ahmed M Musa; Andres Gutierrez; Brima M Younis; Kawthar A M Salih; Ahmed M El-Hassan
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

5.  Leishmania donovani-specific 25- and 28-kDa urinary proteins activate macrophage effector functions, lymphocyte proliferation and Th1 cytokines production.

Authors:  Vinod Kumar; Jalaj K Gour; Nisha Singh; Surabhi Bajpai; Rakesh K Singh
Journal:  Parasitol Res       Date:  2013-01-19       Impact factor: 2.289

6.  Evaluation of s.c. route of immunization by homologous radio attenuated live vaccine in experimental murine model of visceral leishmaniasis.

Authors:  Sanchita Datta; Supriya Khanra; Anindita Chakraborty; Syamal Roy; Madhumita Manna
Journal:  J Parasit Dis       Date:  2014-09-20

Review 7.  Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.

Authors:  Lynn Soong; Calvin A Henard; Peter C Melby
Journal:  Semin Immunopathol       Date:  2012-10-11       Impact factor: 9.623

8.  Influence of genetic variants of gamma interferon, interleukins 10 and 12 on Visceral Leishmaniasis in an endemic area, Iran.

Authors:  Mehdi Kalani; Maral Choopanizadeh; Manoochehr Rasouli
Journal:  Pathog Glob Health       Date:  2019-01-15       Impact factor: 2.894

9.  Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.

Authors:  Robert G Schaut; Tara L Grinnage-Pulley; Kevin J Esch; Angela J Toepp; Malcolm S Duthie; Randall F Howard; Steven G Reed; Christine A Petersen
Journal:  Vaccine       Date:  2016-09-21       Impact factor: 3.641

Review 10.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.